Erythroid cell patterns in neoplasms show distinct genomic profile and poor venetoclax response, new research suggests.

Shorter venetoclax durations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) yielded comparable survival outcomes in a new study, challenging treatment norms ...

Updated data from the BEXMAB study reveals a significant increase in complete remission rates for patients with high-risk ...

AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival.

One patient assigned to ibrutinib-venetoclax developed myelodysplastic syndrome / acute myeloid leukemia (AML), as did eight patients assigned to FCR.

And I think we'll get into, you know, the probably greatest unmet need is, once we do fail HMA-based therapy, particularly for higher risk myelodysplastic syndrome patients, there's really nothing.

Source Reference: Bataller A, et al "Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre ...

The study evaluated a combination therapy involving its blockbuster cancer drug Venclexta (venetoclax) in newly diagnosed patients with higher-risk myelodysplastic syndrome (MDS).

First-line therapy was hypomethylating agent (HMA) monotherapy, lenalidomide, and venetoclax (20, 2, and 2 percent, respectively); the remaining patients were treated with supportive care.